Annovis Bio ANVS

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.04 (+2.34%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Annovis Bio (ANVS)
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $1.74

  • Market Cap

    $33.91 Million

  • Price-Earnings Ratio

    -0.44

  • Total Outstanding Shares

    19.49 Million Shares

  • Total Employees

    6

  • Dividend

    No dividend

  • IPO Date

    January 29, 2020

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    New York Stock Exchange

  • Type

    Common Stock

  • Headquarters

    101 lindenwood drive, suite 225, Malvern, PA, 19355

  • Homepage

    https://www.annovisbio.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$-22.97 Million
Net Cash Flow From Financing Activities, Continuing$29.26 Million
Net Cash Flow From Investing Activities$-6.28 Million
Net Cash Flow, Continuing$0
Net Cash Flow From Operating Activities, Continuing$-22.97 Million
Net Cash Flow From Financing Activities$29.26 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Preferred Stock Dividends And Other Adjustments$0
Other Operating Expenses$6.50 Million
Nonoperating Income/Loss$-10.54 Million
Diluted Average Shares$11.76 Million
Revenues$0
Basic Earnings Per Share$-3.97

Comprehensive Income

October 1, 2023 to September 30, 2024
MetricValue
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Other Comprehensive Income/Loss$0
Comprehensive Income/Loss Attributable To Parent$-40.94 Million
Comprehensive Income/Loss$-40.94 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Liabilities$1.91 Million
Wages$553,710
Equity Attributable To Parent$7.06 Million
Current Liabilities$5.39 Million
Liabilities$7.30 Million
Assets$14.36 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ANVS from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    â“’ 2025 Financhle. All Rights Reserved.